The Latest Research on ADHD

Published Online: Wednesday, April 17, 2013
Follow Pharmacy_Times:
In this podcast, which is part of the virtual AD/HD conference podcast series, Kenny Handelman, MD, discusses what is new and interesting in the world of ADHD research—and cautions against being taken in by sensational media accounts of this research. To listen to this podcast online, click here.
Related Articles
The FDA has added a new warning to the drug label of the methylphenidate transdermal system indicated for ADHD to describe permanent loss of skin color, also known as chemical leukoderma.
An increasing number of adults receiving prescription stimulant medications challenge the notion that ADHD is a children’s condition and create new obstacles for pharmacists.
Four separate drug manufacturers have launched generic versions of Shire’s Intuniv ADHD treatment for children aged 6 to 17 years.
The FDA had accepted for review Tris Pharma’s New Drug Application for its extended-release liquid amphetamine to treat ADHD in children.
Latest Issues
$auto_registration$